Archives: Agenda

ROUNDTABLE SESSIONS 嘉宾主持圆桌讨论会

During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

ROUNDTABLE 1

What key aspects of inspection readiness should be considered right now?

Hosted By Claire Qin, Chief Strategy Officer, Intelligen AI; BioPharma Investor

ROUNDTABLE 2

Getting the best out of your sponsor – CRO partnership

Hosted by Megan Qin, Head of Medical Device Clinical Excellence Working Group, CMAC

ROUNDTABLE 3

Ensuring clinical quality assurance in supply chain management

Hosted By Daniel Gao, President, ISPE Supply Chain Committee

互动式圆桌会议为您提供与同行深入交流的独特机会，共同探讨行业关键挑战的解决方案并分享最佳实践。每场讨论由行业专家主持，聚焦单一议题，通过高互动形式拓展人脉网络，汲取他人经验智慧。
（每场圆桌讨论时长30分钟，参会者可轮换参与）

圆桌议题1：中国药企出海的机遇与挑战
主持嘉宾：秦祯，首席战略官，Intelligen AI

圆桌议题2：如何构建最优申办方-CRO合作伙伴关系
主持嘉宾：秦飞，卓越临床联盟医疗器械工作组负责人，CMAC

圆桌议题3：临床试验供应链质量管理保障机制
主持嘉宾：高晓伟，主席，ISPE供应链分会

Patient Centricity in Clinical Trials: A New Era in China 以患者为中心的临床试验：中国新时代

As China’s clinical trial ecosystem evolves, there is a growing emphasis on patient-centric approaches to improve recruitment, retention, and overall trial outcomes. This session will explore strategies to enhance patient engagement, leverage digital health solutions, and address cultural and regulatory considerations for patient-centric clinical trials in China.

  • Understanding the Shift Toward Patient- Centric Trials in China.
  • Enhancing Patient Recruitment and Retention
  • Digital Health and Remote Monitoring in Patient- Centric Trials.
  • Regulatory and Ethical

随着中国临床试验生态系统的演进，聚焦患者需求的 模式正显著提升受试者招募、留存及整体试验质量。 本环节将探讨如何通过数字化健康解决方案增强患者 参与度，并解析中国患者中心式试验中的文化适应性 与监管要求

  • 去中心化临床试验 DCT 的发展历程
  • 国内外相关法规对 DCT 的指导要求
  • DCT 技术在临床研究中的具体应用和实践
  • 关于 DCT 发展趋势的展望和应对。

AI-Driven New Paradigm for Healthcare AI 驱动的医疗健康新范式

  • Government & Regulation: From “Approver” to “Ecosystem Cultivator and Rule-Maker”.
  • Pharmaceutical Companies: From “Drug Suppliers” to “Key Ecosystem Builders and Enablers”.
  • Medical Institutions: From “Service Endpoints” to “Data-Driven Innovation Hubs”.
  • Patient Population: From “Passive Recipients” to “Empowered Active Health Partners”.
  • 政府与监管：从“审批者”到“生态培育者与规则制定者
  • 医药企业：从”药品供应商“到”生态系统的关键构建者与赋能者“
  • 医疗机构：从“服务终端”到“数据驱动的创新协同中心”
  • 患者群体：从”被动受众“到”自我赋能的主动健康伙 伴